Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease

scientific article published on 13 June 2014

Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/ANA.24186
P698PubMed publication ID24852682
P5875ResearchGate publication ID262573460

P50authorAlzheimer's Disease Neuroimaging InitiativeQ4738819
Jordi ClarimónQ38327609
Daniel A. AlcoleaQ41362963
María Carmona-IraguiQ43551870
Eduard VilaplanaQ57002404
P2093author name stringAlberto Lleó
Rafael Blesa
Juan Fortea
Isabel Sala
María-Belén Sánchez-Saudinos
Sofía Antón-Aguirre
Estrella Morenas
Jordi Pegueroles
Santiago Medrano
Sofía González
P2860cites workToward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseQ24595802
Measuring the thickness of the human cerebral cortex from magnetic resonance imagesQ29615080
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse modelQ29617937
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersQ29620245
Amyloid burden and neural function in people at risk for Alzheimer's DiseaseQ33599047
Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer diseaseQ33699415
Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's diseaseQ33709263
Brain changes in older adults at very low risk for Alzheimer's diseaseQ33729050
Tau is essential to beta -amyloid-induced neurotoxicityQ34029253
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's diseaseQ34157492
A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse modelQ34162478
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.Q34514638
Amyloid-β associated cortical thinning in clinically normal elderlyQ35053524
Amyloid-β associated volume loss occurs only in the presence of phospho-tauQ36010484
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tauQ36177140
Brain injury biomarkers are not dependent on β-amyloid in normal elderlyQ36863815
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individualsQ37090083
Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neuronsQ37221892
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsQ37227424
Beta-amyloid burden is not associated with rates of brain atrophyQ37326537
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer diseaseQ37332710
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderlyQ37391300
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort studyQ37524511
Alzheimer disease: Aβ-independent processes-rethinking preclinical AD.Q37604297
Tau pathology and neurodegenerationQ38107632
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.Q39173722
Longitudinal regional brain volume changes quantified in normal aging and Alzheimer's APP x PS1 mice using MRI.Q39877007
Frequency of stages of Alzheimer-related lesions in different age categoriesQ42445469
Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia.Q43738741
Larger temporal volume in elderly with high versus low beta-amyloid depositionQ43965311
Apolipoprotein E ε4-related thickening of the cerebral cortex modulates selective attentionQ44110544
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's diseaseQ44191043
Synaptic contact number and size in stratum radiatum CA1 of APP/PS1DeltaE9 transgenic mice.Q47242407
Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4.Q48341077
Phases of A beta-deposition in the human brain and its relevance for the development of AD.Q48567985
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.Q48893777
Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas.Q51011713
P433issue2
P921main subjectAlzheimer's diseaseQ11081
cerebrospinal fluidQ54196
biomarkerQ864574
P304page(s)223-230
P577publication date2014-06-13
P1433published inAnnals of NeurologyQ564414
P1476titleCerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease
P478volume76